Establishment of effective non-animal alternatives for developmental toxicity screening assays is desirable to ensure maternal and fetal health outcomes. Validation of such assays requires a comparison between the in vitro responses to chemical exposures and the in vivo impacts of the corresponding compounds at equivalent concentrations. Here, we investigated how the P19C5 gastrulation model responds to 24 compounds at specific concentrations, some of which are categorized as positive exposures based on previously observed detrimental effects on development in vivo, whereas others are categorized as negative exposures due to lack of effects in vivo. The P19C5 gastrulation model consists of in vitro morphogenesis of mouse stem cells aggregated into embryoid bodies (EBs), which recapitulates growth and axial elongation of early embryos during four days of three-dimensional culture. Adverse impacts of chemical exposures were defined as: death, impaired growth, and altered axial elongation of EBs. Ten out of 17 positive exposures caused adverse impacts on EBs. In contrast, only three out of 17 negative exposures adversely affected EBs, although two of the three diminished viability of somatic cell lines (NIH/3T3, HEK293, and JEG3), suggesting general cytotoxicity. Overall, the study showed that 24 out of 34 exposures impacted EB development in a manner concordant with the in vivo developmental effects. Validation of other alternative assays using the same set of chemical exposures will provide information on the strengths and weaknesses of each assay, and should help determine the most effective ensemble of assays to detect a wide range of developmentally toxic exposures.
In vitro model systems, particularly those using pluripotent stem cells, are promising screening tools for chemical exposures that cause developmental toxicity. Pluripotent stem cells, such as embryonic stem (ES) cells, can differentiate into multiple tissue types in vitro and display embryo-like properties. Thus, pluripotent stem cells can recapitulate certain aspects of embryonic development and serve as in vitro models to demonstrate the impacts of developmentally toxic chemical exposures. ES cell tests, or ESTs, evaluate the developmental toxicity of compounds based on their inhibitory effects on ES cell differentiation (Riebeling et al., 2012; Theunissen and Piersma, 2012) , but each individual EST system recapitulates only a limited aspect of embryonic development, i.e., differentiation of cardiomyocytes, neurons, or osteoblasts. Thus, it is more likely that a panel of complementary in vitro systems-each representing distinct aspects of embryonic development-can comprehensively screen a broad range of chemical compounds that inflict developmental toxicity.
To assemble a panel of complementary assays, each assay must undergo a series of validation studies using compounds with known developmental toxicities to assess its applicability and limitations. However, selection of proper reference compounds to validate in vitro screening assays has been challenging, partly because developmental impact of compounds varies depending on timing, dose, and duration of exposure to embryos (Friedman, 2010; Jel ınek, 2005) . For example, a given compound can exert developmental toxicity when exposed at a high dose, but the same compound may pose no risk at lower doses (Daston et al., 2010) . Therefore, dichotomic designation of compounds as developmental toxicants or non-toxicants is ineffectual in properly validating assays. To that end, Daston et al. (2014) have proposed an "exposure-based validation list" for developmental toxicity screening assays. This list (referred hereafter as the Daston list) consists of 20 positive exposures known to cause embryo-fetal death or structural malformation in rats, and 19 negative exposures, which have no adverse impacts on rat embryo development. Eleven of these compounds demonstrate both a positive exposure at a high concentration and a negative exposure at a low concentration. The Daston list is a significant step forward in validating in vitro assays for developmental toxicity screening.
The objective of the present study is to validate the in vitro gastrulation model of P19C5 stem cells using the compounds on the Daston list. P19C5 cells are mouse embryonal carcinoma stem cells that possess properties similar to the pluripotent epiblast lineage of postimplantation embryos. Three-dimensional culture of P19C5 cell aggregates results in spontaneous differentiation of mesendoderm along with steady increase in size and axial elongation (Lau and Marikawa, 2014) . This morphogenetic transformation of P19C5 cell aggregates, or embryoid bodies (EBs), resembles gastrulation, the morphogenetic process of early embryonic development that creates the germ layers and elongated body shape along the anterior-posterior axis. Growth and axial elongation of the P19C5 gastrulation model are impaired by pharmacological inhibitors of the major developmental signals that are crucial for embryo body patterning, namely Wnt, Nodal, Fgf, and retinoic acid signaling pathways (Li and Marikawa, 2015) . The morphogenesis of P19C5 EBs is also sensitive to various therapeutic drugs that are contraindicated for use during pregnancy (Warkus et al., 2016) . Furthermore, valproic acid (VPA) at 0.8 mM, one of the positive exposures in the Daston list, affects the P19C5 morphogenesis, such that VPAtreated EBs are smaller, distorted, and less elongated (Li and Marikawa, 2016) . These studies suggest that the P19C5 gastrulation model can serve as an effective in vitro tool to detect developmentally toxic chemical exposures.
Here, we validated the P19C5 gastrulation model using the 34 exposures compiled in the Daston list. While the morphology-based assay correctly classified many of the Daston exposures, the present study also revealed some limitations of the assay based on the cases where exposures were misclassified.
MATERIALS AND METHODS
Test compounds. Compounds of the Daston list (Daston et al., 2014) used in the present study are shown in Table 1 . Four compounds in the Daston list, namely HEPP (positive exposure), SB-209770 (positive and negative exposures), tapentadol (negative exposure), and VPA (positive exposure), were not evaluated for the following reasons. HEPP and SB-209770 were unavailable from major chemical suppliers. Tapentadol was available from one supplier (Sigma-Aldrich, St Louis, Missouri) as a solution of 1.0 mg/mL dissolved in methanol (Catalog Number T-058). However, to achieve the concentration indicated in the Daston list (252 mg/L), about 25% of the culture medium would be methanol, which is not compatible with our assay (see below). The morphogenetic effect of VPA on the P19C5 gastrulation model has been evaluated previously, including the concentration cited in the Daston list (0.8 mM) (Li and Marikawa, 2016) . Note that the concentration of desloratadine indicated in the Daston study (1.5 mM) (Daston et al., 2014 ) is apparently a typographical error, as the original study referenced therein (FDA, 2001) indicates 1.5 lM instead. Accordingly, desloratadine was evaluated at 1.5 lM as a negative exposure in the present study.
Cell culture. P19C5 cells, a subline of P19 mouse embryonal carcinoma cell line (Lau and Marikawa, 2014) , were propagated in culture medium (Minimum Essential Medium Alpha with nucleosides and GlutaMAX Supplement [LifeTechnologies, Carlsbad, California] , 2.5% fetal bovine serum, 7.5% newborn calf serum, 50 units/mL penicillin, and 50 lg/mL streptomycin). Embryoid bodies of P19C5 cells were generated according to the method previously described for P19 cell aggregates (Marikawa et al., 2009) . Briefly, P19C5 cells were fully dissociated with Trypsin-EDTA, and suspended in culture medium containing 1% dimethyl sulfoxide (DMSO) at the density of 10 cells/lL with or without specific amount of a test compound (Figure 1 ). Drops (20 lL each) of cell suspension were spotted on the inner surface of Petri dish lids for hanging drop culture. NIH/3T3 (derived from mouse embryonic fibroblast), HEK293 (derived from human embryonic kidney), and JEG3 (derived from human choriocarcinoma) were obtained from the American Type Culture Collection (Manassas, Virginia), and propagated in culture medium (Dulbecco's Modified Eagle Medium, GlutaMAX Supplement [LifeTechnologies], 10% fetal bovine serum, 50 units/mL penicillin, and 50 lg/mL streptomycin).
Image analysis. Embryoid bodies were removed from hanging drops and grouped together for photography using an AxioCam MRm digital camera connected to an Axiovert 200 microscope with Hoffman modulation-contrast optics (Carl Zeiss, Thornwood, New York). Image files were converted to JPEG format and opened in ImageJ (http://rsb.infonihgov/ij). Morphological parameters of individual EBs were measured on ImageJ by tracing their circumference. In the previous studies (Lau and Marikawa, 2014; Li and Marikawa, 2015; Warkus et al., 2016) , tracing of EB circumference was performed manually using the polygon selection tool. In the present study, however, we formulated a series of program operations to enable tracing of EB circumference with less user-dependent variability. The details of the program operations are described in Supplementary Data. Briefly, the first set of operations (e.g., Image Calculator, Find Edges, Brightness/Contrast and Binary) was applied to convert the inside of EBs into solid black while the background became white. The second set of operations (e.g., Analyze Particles and Fit Splines) was applied to detect the outlines of blackened areas, corresponding to the perimeter of EBs. The third set of operations (e.g., Measure) was applied to selected regions of interest (ROI) to determine their morphological parameters, namely area and circularity (¼ 4 Â p Â area/ perimeter 2 ). Measurements were exported to Microsoft Excel, where Elongation Distortion Index (EDI ¼ 1/circularity À 1) was calculated. As described previously, area was used as a proxy for the size of EB, whereas EDI was used to gauge the extent of EB axial elongation (Warkus et al., 2016) .
Viability assay. The impact of drugs on cell proliferation and viability was evaluated using CellTiter-Glo Luminescent Cell Viability Assay system (Promega, Madison, Wisconsin), which determines the number of live cells in culture by measuring the amount of ATP as a quantitative proxy for the number of metabolically active cells. P19C5, NIH/3T3, HEK293, and JEG3 cells were seeded in 96-well plates at the density of 100, 250, 250, and 500 cells/well, respectively, and were cultured in the corresponding medium (100 lL/well) supplemented with 1% DMSO with or without specific amount of a test compound. After 4 days of culture, cells were treated with CellTiter-Glo Reagent for measurement of luminescence, as a readout of ATP amount, according to the manufacturer's instruction (Promega), using Gene Light 55 Luminometer (Microtech, Chiba, Japan). Cell seeding density was optimized through a series of pilot experiments, to confirm that cell numbers at the end of 4 days of culture were proportionate to intensities of luminescence. Relative cell number was calculated based on ratio of the luminescence intensity in compound-treated cells to that in non-treated cells of the same set of experiments. For each compound exposure, three sets of experiments were conducted as biological replicates.
Statistical analyses. Experiments to assess morphological impacts of compound exposures on EB morphology were conducted in three biological replicates using different collections of cell suspensions. For each replicate, 16 hanging drops were generated per exposure (a specific concentration of compound) in parallel with 16 control (i.e., no compound) hanging drops ( Figure 1 ). Area and EDI of individual Day 4 EBs were normalized against the average of control EBs, and defined as relative area and relative EDI, respectively, expressed in percentages (i.e., averages of relative area and relative EDI of control EBs are 100%). Data from three replicates were compiled, and their averages are shown with 95% confidence intervals ( Figure 2 ). Thus, a total of 45-48 EBs were scored for each exposure (1 or 2 EBs were occasionally lost or damaged during operations). To verify that observed effects on EBs were statistically significant, twosample t-test was performed between compound-treated group and the matching control group. All morphological impacts that were defined as adverse in the present study (see below) were statistically significant (P < .01).
Experimental design. The overall experimental scheme is shown in Figure 1 . In the present study, we examined several concentrations for each compound in addition to those in the Daston list (Daston et al., 2014) . Particularly, when positive exposures in the Daston list had no apparent effect on P19C5 EBs, higher concentrations were also evaluated. EBs were observed daily for survival and integrity, and were photographed on the fourth day of culture (Day 4) for morphometric analyses. Impact of each compound exposure was assessed based on changes in area or EDI relative to control EBs. In the present study, a compound exposure was classified as having an adverse effect on EB morphogenesis when it caused either of the following three outcomes: (1) degeneration (i.e., death) of EBs at any time point in culture or cell aggregation failure, (2) a reduction in the average area by more than 20% relative to control EBs, and (3) a decrease or increase in the average EDI by more than 40% relative to control EBs. Note that an increase in the average EDI accompanied by an increase in the average area was not classified as adverse, because such condition suggests that the exposure promoted EB growth and morphogenesis rather than impairing EB development (see Discussion section).
RESULTS

Effects of the Positive and Negative Exposures on EB Morphogenesis
Morphogenetic impacts of compound exposures on P19C5 EBs are shown in Figure 2 , and summarized in Tables 2 and 3 respect to specific concentrations indicated in the Daston list. Sample images of EBs, namely those that were distinctly affected by exposures, are shown in Figure 3 . Based on the classification criteria described in Materials and Methods section, 58.8% (10 out of 17) of the positive exposures tested had adverse impact on P19C5 EBs (Table 2) . Specifically, acetazolamide (120 lM) reduced relative area by 25% and reduced relative EDI by 45%; all-trans retinoic acid (ATRA; 200 nM) reduced relative area by 60% and reduced relative EDI by 90%; caffeine (325 lM) increased relative EDI by 70%; hydroxyurea (350 lM) caused death; mono(2-ethylhexyl) phthalate (MEHP; 150 lM) reduced relative area by 25%; methoxyacetate (5 mM) reduced relative area by 25% and reduced relative EDI by 90%; methylmercury (5 lM) caused death; nilotinib (28 lM) prevented cell aggregation (without apparent cell death); ramelteon (80 lM) increased relative EDI by 45%; and salicylic acid (3 mM) reduced relative area by 60%. In contrast, only 17.6% (3 out of 17) of the negative exposures exhibited adverse effects on EB development (Table 3) . Namely, butylparaben (110 lM) reduced relative area by 55%; nilotinib (2 lM) reduced relative area by 25% and increased relative EDI by 60%; and propylene glycol (850 mM) caused death. Overall, a significantly higher percentage of the positive exposures exhibited adverse impacts on EBs than the negative exposures (P ¼ .013; Chi-square test).
No adverse effect was observed in the P19C5 gastrulation model in response to seven of the Daston list positive exposures, namely abacavir (80 lM), artesunate (20 nM), dabigatran (7 lM), ethylene glycol (57 mM), fingolimod (67 nM), glycolic acid (5 mM), and methanol (270 mM). Thus, we further examined whether EBs could be affected by these compounds at higher Artesunate, fingolimod, or methanol did not show any adverse effect on EB morphogenesis even at four times higher concentrations (Figure 2) , suggesting that the P19C5 gastrulation model is unable to detect developmental toxicity of these compounds at physiologically relevant concentrations. However, abacavir at four times higher concentration (320 lM) reduced relative area by 25%; dabigatran at two times higher concentration (14 lM) reduced relative area by 21%; ethylene glycol at four times higher concentration (228 mM) reduced relative area by 25%; and glycolic acid at four times higher concentration (20 mM) reduced relative area by 80% and reduced EDI by 70%. This suggests that the P19C5 gastrulation model may still be able to detect developmentally toxic exposures of these compounds, albeit with slightly less sensitivity than in vivo assays.
Ten of the Daston compounds evaluated (abacavir, ATRA, caffeine, dabigatran, ethylene glycol, glycolic acid, MEHP, methanol, nilotinib, and ramelteon) are categorized with both positive and negative exposures depending on concentrations. Such compounds are the most useful to rigorously validate the sensitivity and the specificity of screening assays (Daston et al., 2014) . According to the classification criteria described in Materials and Methods section, the P19C5 EB model was able to distinguish between positive and negative exposures for four of these compounds (ATRA, caffeine, MEHP, and ramelteon). If four times higher concentrations were also to be included for positive exposures, then additional four compounds (abacavir, dabigatran, ethylene glycol, and glycolic acid) can also be differentially classified by the P19C5 EB model.
While not directly related to the exposures indicated in the Daston list, additional concentrations were also evaluated for 12 compounds to determine their lowest-observed-adverseeffect level (LOAEL) and/or no-observed-adverse-effect level (NOAEL) with respect to morphogenetic impact. The results of 
FIG. 3. Representative images of P19C5 EBs. Not all compound exposures are shown (see text)
. Each set of images shows a control group of EBs (no test compound) and one or two compound-treated groups of EBs, made from the same cell suspension as the control. Scale bars ¼ 500 lm.
morphogenetic analyses of those exposures are shown in Supplementary Figure. LOAEL and NOAEL of all 24 compounds are summarized in Table 4 .
Cytotoxicity on Somatic Cell Lines
Three of the negative exposures adversely impacted the P19C5 gastrulation model. Namely, butylparaben and nilotinib reduced EB size, whereas propylene glycol caused death of EBs. Thus, these negative exposures appeared to be detrimental to growth or survival of P19C5 EBs, raising the possibility that the gastrulation model may be overly sensitive to these compound exposures, leading to misclassifications. To test whether harmful effects of these exposures are unique to the P19C5 EBs, we performed cell viability assay using monolayer cultures of P19C5 cells as well as three types of somatic cell lines, NIH/3T3 (mouse embryonic fibroblast-derived), HEK293 (human embryonic kidney-derived), and JEG3 (human trophoblast-derived). These cell lines were cultured for 4 days in the presence of butylparaben, nilotinib, or propylene glycol, and impact on cell proliferation or survival was scored. All cell lines were completely killed by propylene glycol at the negative exposure concentration (850 mM) (Figure 4 ). Butylparaben at the negative exposure concentration (110 lM) also consistently reduced relative cell numbers of all four cell lines (Figure 4) . Thus, on one hand, these two negative exposures appeared to exhibit cytotoxic effects on not only P19C5 cells but also on other cell lines.
On the other hand, relative cell numbers were not consistently reduced by nilotinib in any of the cell lines at the negative exposure concentration (2 lM) (Figure 4 ).
DISCUSSION
The present study evaluated our in vitro gastrulation model of P19C5 stem cells in reference to the Daston list of compound exposures for developmental toxicity assays. Based on the morphogenetic effects on EBs, 10 out of 17 positive exposures were classified as adverse, whereas 14 out of 17 negative exposures were non-adverse. As shown in the previous study, VPA at 0.8 mM, another positive exposure in the Daston list, also adversely affects P19C5 EB morphogenesis (Li and Marikawa, 2016) . Thus, altogether, 25 out of 35 exposures in the Daston list (71.4%) were correctly classified by the morphology-based assay using the P19C5 gastrulation model. When up to four times higher concentrations are included in assessment of the positive exposures, four additional exposures were also classified correctly, bringing the total to 29 out of 35 (82.9%), although the validity of such an ad hoc criterion will require additional biological and toxicological justification. To date, various types of non-animal alternatives have been explored as developmental toxicity screening assays, including those utilizing differentiation, migration, or metabolomics of mouse or human ES cells (Kuske et al., 2012; Palmer et al., 2013; Seiler and Spielmann, 2011; Theunissen and Piersma, 2012; Xing et al., 2015) , rodent whole embryo culture (Piersma et al., 2004) , micromass culture of limb bud mesenchyme (Pratten et al., 2012) , and non-mammalian model systems, namely zebrafish embryos (Sipes et al., 2011) . At present, it may not be fruitful to discuss effectiveness of the P19C5 gastrulation model in comparison with these assays, because no validation studies have been reported in reference to the Daston list, to the best of our knowledge. Evaluations of other non-animal alternatives using the Daston list should provide solid framework for direct comparisons between different assays to reveal their strengths and weaknesses, and help to assemble a proper battery of tests to screen a broad range of developmentally toxic chemical exposures.
In the present study, the effects of compound exposures on the P19C5 gastrulation model were evaluated solely based on the morphological features, namely the size and shape of EBs. However, the effects of compounds may also be evaluated through gene expression analyses, because P19C5 EBs exhibit distinct temporal and spatial gene expression patterns that are characteristic of early embryogenesis during axial elongation and patterning (Lau and Marikawa, 2014; Li and Marikawa, 2015; Marikawa et al., 2009) . Effects on gene expression are generally considered to be more sensitive endpoints when assessing developmental toxicity, and various types of gene expression analyses have been incorporated into stem cell-based in vitro assays, particularly ESTs, to augment their detection of developmental toxicity (Buesen et al., 2009; Gao et al., 2014; PanzicaKelly et al., 2013; Pennings et al., 2011; Suzuki et al., 2011; Yu et al., 2015; zur Nieden et al., 2001) . This notion applies to the response of P19C5 EBs to DAPT, a pharmacological inhibitor of Notch signaling, which markedly down-regulates expression of somitogenesis regulator genes, such as Hes7, Lfng, and Nrarp, without significantly altering EB size or shape (Li and Marikawa, 2015) . However, the use of gene expression analyses to detect developmental toxicity requires cautious interpretation, as the heightened sensitivity may increase the rate of false-positive results. Mouse genetic studies, using the targeted gene knockout technology, have demonstrated in various cases that the loss of important developmental regulator genes fails to cause overt phenotypic abnormalities, due to existence of compensatory or redundant mechanisms (Barbaric et al., 2007; Nowak et al., 1997) . Thus, alterations in gene expression may not correlate with the dramatic phenotypic effects (e.g. embryonic death or major fetal malformations) referenced in the Daston list. Among the 34 exposures from the Daston list examined here, the negative exposure of ATRA (1.7 nM) was particularly unique in that it markedly increased relative area of EBs. Because relative EDI was concomitantly increased, ATRA at the low concentration appeared to promote growth and axial elongation of EBs. Although ATRA is teratogenic at excessively high concentrations, it also acts at low physiological concentrations as an endogenous regulator of cell proliferation and embryo body patterning (Clagett-Dame and Knutson, 2011) . Inactivation of Aldh1a2 gene, which encodes retinaldehyde dehydrogenase to synthesize ATRA, impairs growth and axial elongation in mouse embryos (Niederreither et al., 1999) . Likewise, treatment of P19C5 EBs with BMS493, a pharmacological antagonist of retinoic acid receptors, reduces relative area and EDI, suggesting that active retinoic acid signaling is essential for growth and axial elongation in the in vitro gastrulation model (Li and Marikawa, 2015) . The source of retinoic acid or its precursors in the culture medium used in the present study was possibly bovine serum (Materials and Methods section), and it may not have contained sufficient amount to support maximal growth and axial elongation of EBs. Thus, supplementation of a small amount of ATRA (as in the case for 1.7 nM exposure) would be beneficial for more robust EB development in vitro.
Artesunate, fingolimod, and methanol caused no adverse effects on the P19C5 gastrulation model even at four times higher concentrations than those indicated as positive exposures in the Daston list. These false negatives may exemplify some of the limitations and weaknesses of the model. Artesunate, an anti-malaria medication, is rapidly converted to its active metabolite dihydroartemisinin, which exerts developmental toxicity by generating free radicals that damage embryonic erythroblasts Li et al., 2009) . Depletion of primitive embryonic erythroblasts likely accounts for the observed cardiovascular and skeletal abnormalities caused by artesunate treatment (Clark, 2009; Clark et al., 2008; White and Clark, 2008; White et al., 2006) . The developmental toxicity of fingolimod, an immunomodulator, also manifests as abnormal vascular maturation and cardiac malformation, mediated by inhibition of the sphingosine-1 phosphate receptor (FDA, 2010; Schmid et al., 2007) . The P19C5 gastrulation model may not accurately identify such developmental toxicity that selectively disrupts hematologic processes, because in vitro development of EBs does not require a vascular system. On the other hand, the developmental toxicity of methanol may be mediated by its metabolic byproduct, formate (Andrews et al., 1995) . Compounds that become teratogenic only after chemical modifications by maternal metabolism are termed, "proteratogens" (Wells and Winn, 1996) . Detection of proteratogens is often considered a weakness of in vitro screens for chemicals that inflict developmental toxicity, because these assays usually lack the maternal metabolic system. Future studies will address whether the P19C5 model is susceptible to formate, and explore the incorporation of an exogenous metabolic activation system, such as co-culture with hepatocytes (Hettwer et al., 2010; Oglesby et al., 1986) or liver microsome fractions (Luijten et al., 2008; Zhao et al., 1993) .
Practically speaking, misclassification of negative exposures (i.e., false positives) may be more detrimental for effectiveness of developmental toxicity assays, as compared with misclassification of positive exposures (i.e., false negatives). Unnecessary dismissal of safe compound exposures based on incorrect assay outcomes is disadvantageous for pharmaceutical development and burdensome for regulatory agencies (Waring et al., 2015) . In the case of the P19C5 gastrulation model, three negative exposures gave false-positive outcomes: butylparaben at 110 lM (reduction in area by 55%), nilotinib at 2 lM (reduction in area by 25% and increase in EDI by 60%), and propylene glycol at 850 mM (death). The butylparaben and propylene glycol exposures diminished proliferation or survival of three somatic cell lines. Such general cytotoxicity may lead to misclassification of these exposures by other in vitro assays as well. It is unclear how such cytotoxic exposures are apparently harmless to developing embryos in vivo (Daston et al., 2014) . It is important to note that the compound concentrations indicated in the Daston list are C max , and, therefore, developing embryos may not be exposed to such concentrations in a continuous manner, especially when compound clearance by the mother is rapid. Indeed, both butylparaben and propylene glycol have elimination halflives of approximately 4 h and undergo biotransformations in vivo (Aubert et al., 2012; Morshed et al., 1988) . Additional pharmacokinetics information, namely area under the curve (AUC), may be more applicable to in vitro experimental conditions, and may help resolve this potential discrepancy. In contrast, the nilotinib negative exposure did not consistently diminish proliferation of the somatic cell lines or P19C5 cells in monolayer culture, suggesting that the adverse effect was specific to the P19C5 gastrulation model. Interestingly, nilotinib at the high concentration (28 lM; positive exposure in the Daston list), exhibited an unusual impact, i.e., P19C5 cells in hanging drops failed to aggregate while they were still alive and proliferating. Although spontaneous cell aggregation is an essential step in generating EBs, this process does not correspond to normal embryonic development. Thus, nilotinib may be altering cellular properties that are not embryologically relevant, and such non-physiological effects of nilotinib, even at lower concentrations, may have contributed to the false-positive misclassification.
In the future, the exposure-based validation list (Daston et al., 2014) will likely be expanded and refined as additional in vivo data on developmental toxicity and pharmacokinetics become available for various compounds. As previously suggested (Wise, 2016) , it may be important to categorize positive exposures into distinct groups according to severity and nature of developmental toxicity. For example, the mechanism of an exposure that results in embryonic death is fundamentally different from an exposure that causes spina bifida or microcephaly. Should such differences in in vivo impact be reflected in the outcomes of in vitro assays? In the present study, the P19C5 gastrulation model exhibited various responses to the positive exposures, ranging from total degeneration to a reduction in axial elongation. The range of phenotypic responses warrants further investigations to examine whether these variations in EB integrity and morphology correlate with the nature and severity of in vivo effects observed after exposure to the corresponding developmentally toxic compounds.
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